{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:30:20Z","timestamp":1793374220282,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Cardiac rhabdomyoma (CRHM) is the principal cardiac tumor in children and is most often associated with tuberous sclerosis complex (TSC). Mutations in the <jats:italic>TSC1<\/jats:italic> and <jats:italic>TSC2<\/jats:italic> genes cause the overactivation of the mammalian Target of Rapamycin (mTOR). This protein family is responsible for abnormal cell proliferation leading to the formation of CRHMs and hamartomas in other organs. Despite the tendency for spontaneous regression, some CRHMs can cause heart failure and intractable arrhythmias, requiring surgical resection. In recent years, the use of everolimus and sirolimus (mTOR inhibitors) in the treatment of CRHMs has been reported. We report two cases of neonates with giant rhabdomyomas, with hemodynamic repercussions treated with low-dose everolimus (4.5\u2005mg\/m<jats:sup>2<\/jats:sup>\/week). In both cases, we obtained an approximate decrease of 50% in the total area of the mass after three weeks of treatment. Despite rebound growth after stopping the drug, we were able to evidence that the use of low doses of everolimus immediately after birth is effective and safe in the treatment of giant CRHMs, avoiding surgical resection of the tumor and associated morbidity and mortality.<\/jats:p>","DOI":"10.3389\/fped.2023.1109646","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T08:08:26Z","timestamp":1676448506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case report: Accelerated regression of giant cardiac rhabdomyomas in neonates with low dose everolimus"],"prefix":"10.3389","volume":"11","author":[{"given":"Daniel","family":"Hurtado-Sierra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy Ximena","family":"Ramos Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyda Z.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Fern\u00e1ndez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Manrique-Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1172-2-11","article-title":"Cardiac tumours in children","volume":"2","author":"Uzun","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.jpedsurg.2007.07.047","article-title":"Fetal and neonatal hepatic tumors","volume":"42","author":"Isaacs","year":"2007","journal-title":"J Pediatr Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.carpath.2007.08.008","article-title":"Pediatric heart tumors","volume":"17","author":"Burke","year":"2008","journal-title":"Cardiovasc Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10024-001-0001-x","article-title":"Study of the regression process in cardiac rhabdomyomas","volume":"5","author":"Wu","year":"2002","journal-title":"Pediatr Dev Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis Complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: a molecular switchboard controlling cell growth","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e001493","DOI":"10.1161\/JAHA.114.001493","article-title":"International tuberous sclerosis consensus G. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the international tuberous sclerosis consensus group","volume":"3","author":"Hinton","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8712962","DOI":"10.1155\/2016\/8712962","article-title":"Regression of cardiac rhabdomyomas in a neonate after everolimus treatment","volume":"2016","author":"Bornaun","year":"2016","journal-title":"Case Rep Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/pediatric13010015","article-title":"Efficacy of everolimus low-dose treatment for cardiac rhabdomyomas in neonatal tuberous sclerosis: case report and literature review","volume":"13","author":"Nespoli","year":"2021","journal-title":"Pediatr Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpeds.2017.06.076","article-title":"Everolimus for the treatment of tuberous sclerosis Complex-related cardiac rhabdomyomas in pediatric patients","volume":"190","author":"Dahdah","year":"2017","journal-title":"J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pd.825","article-title":"Natural history and long-term outcome of cardiac rhabdomyomas detected prenatally","volume":"24","author":"Fesslova","year":"2004","journal-title":"Prenat Diagn"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.jacc.2011.08.005","article-title":"Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia","volume":"58","author":"Miyake","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00431-016-2833-4","article-title":"Identification and clinical course of 166 pediatric cardiac tumors","volume":"176","author":"Shi","year":"2017","journal-title":"Eur J Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2143\/AC.60.5.2004977","article-title":"Right atrial rhabdomyoma acting as the substrate for wolff-Parkinson-white syndrome in a 3-month-old infant","volume":"60","author":"Venugopalan","year":"2005","journal-title":"Acta Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1146","DOI":"10.1542\/peds.2006-0504","article-title":"Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex","volume":"118","author":"Jozwiak","year":"2006","journal-title":"Pediatrics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/uog.5264","article-title":"Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and a meta-analysis","volume":"31","author":"Chao","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00246-016-1528-y","article-title":"Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis Complex","volume":"38","author":"Aw","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1378\/chest.99.1.139","article-title":"Cardiac rhabdomyoma. Rare cause of fetal death","volume":"99","author":"Geva","year":"1991","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1017\/S1047951119003147","article-title":"Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial","volume":"30","author":"Stelmaszewski","year":"2020","journal-title":"Cardiol Young"},{"key":"B20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/2150135118822711","article-title":"Rapid involution of large cardiac rhabdomyomas with everolimus therapy","volume":"12","author":"Garg","year":"2021","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/ped.12816","article-title":"Regression of massive cardiac rhabdomyoma on everolimus therapy","volume":"58","author":"Hoshal","year":"2016","journal-title":"Pediatr Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.3390\/ijerph18094907","article-title":"Treatment of cardiac rhabdomyomas with mTOR inhibitors in children with tuberous sclerosis Complex-A systematic review","volume":"18","author":"Sugalska","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.athoracsur.2015.06.030","article-title":"Treatment strategies for primary tumors of the heart in children: a 10-year experience","volume":"100","author":"Liu","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/2150135117723904","article-title":"Cardiac tumors in pediatric patients: a systematic review","volume":"8","author":"Tzani","year":"2017","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40272-019-00337-7","article-title":"Off-Label use of sirolimus and everolimus in a pediatric center: a case series and review of the literature","volume":"21","author":"Bevacqua","year":"2019","journal-title":"Paediatr Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1017\/S1047951118000598","article-title":"Giant left ventricular rhabdomyoma treated successfully with everolimus: case report and review of literature","volume":"28","author":"Martinez-Garcia","year":"2018","journal-title":"Cardiol Young"},{"key":"B27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1183\/09031936.00210714","article-title":"Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study","volume":"46","author":"Goldberg","year":"2015","journal-title":"Eur Respir J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.14964","article-title":"Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies","volume":"32","author":"Franz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/psp4.12096","article-title":"Characterizing the developmental trajectory of sirolimus clearance in neonates and infants","volume":"5","author":"Emoto","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13023-019-1077-6","article-title":"Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study","volume":"14","author":"Saffari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.pediatrneurol.2015.01.004","article-title":"Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosi(1)s complex","volume":"52","author":"Goyer","year":"2015","journal-title":"Pediatr Neurol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1199","DOI":"10.1542\/peds.2013-3293","article-title":"Rapid regression of left ventricular outflow tract rhabdomyoma after sirolimus therapy","volume":"134","author":"Breathnach","year":"2014","journal-title":"Pediatrics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1017\/S104795112000147X","article-title":"Literature review of international mammalian target of rapamycin inhibitor use in the non-surgical management of haemodynamically significant cardiac rhabdomyomas","volume":"30","author":"Cleary","year":"2020","journal-title":"Cardiol Young"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro Oncol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1109646\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T08:08:30Z","timestamp":1676448510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1109646\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":40,"alternative-id":["10.3389\/fped.2023.1109646"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1109646","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"1109646"}}